Results 191 to 200 of about 68,369 (257)

Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 3, Page 505-519, February 2026.
Background and Purpose Riluzole, approved for amyotrophic lateral sclerosis (ALS), has a glutamate‐modulating profile favourable for mitigating opioid addiction. It reduces neuronal glutamate release and enhances glutamate reuptake, offering advantages over agents that only increase glutamate reuptake.
Ewa Galaj   +7 more
wiley   +1 more source

Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG‐TOP2 Study

open access: yesCancer Science, Volume 117, Issue 2, Page 522-535, February 2026.
In the JCCG‐TOP2 nationwide pediatric cancer genomic profiling study, 204 patients' tumors and peripheral blood from 50 institutions across Japan were successfully analyzed using a dual DNA/RNA panel. A total of 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%),
Kayoko Tao   +38 more
wiley   +1 more source

High prevalence of tetracycline resistance in <i>Neisseria gonorrhoeae</i> across 22 European countries, 2024. [PDF]

open access: yesEuro Surveill
Jacobsson S   +8 more
europepmc   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

open access: yesCell Proliferation, Volume 59, Issue 2, February 2026.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang   +18 more
wiley   +1 more source

Clinical Characteristics, Molecular Diagnosis, and Drug Resistance Profiles of Nontuberculous Mycobacteria Infections: A Retrospective Analysis Using PCR Melting Curve Technology

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Nontuberculous mycobacteria (NTM) are emerging global pathogens. This study aimed to analyze the clinical features, species distribution, and drug resistance profiles of NTM infections in a northern Chinese hospital. A retrospective cohort study included 1769 patients with suspected mycobacterial infection from August 2023 to July 2025.
Kedi Wang   +4 more
wiley   +1 more source

Breakpoint-resolved balanced t(2;12)(q35;q24.31) disrupting <i>HNF1A</i> in multigenerational MODY-3: Diagnostic utility of long-read genome sequencing and therapeutic impact. [PDF]

open access: yesMetabol Open
Rivero-García P   +9 more
europepmc   +1 more source

Pharmacokinetics as a Biomarker

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Pharmacokinetics (PK) has long been differentiated from pharmacodynamics (PD) and biomarkers, yet this distinction undervalues PK's translational relevance. In this Perspective, we propose that PK itself functions as a biomarker that bridges dose, exposure, and response. Using examples from target‐mediated drug disposition, antidrug antibodies,
John A. Wagner   +2 more
wiley   +1 more source

Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales. [PDF]

open access: yesJ Antimicrob Chemother
Baltas I   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy